Genetics

Advances in gene therapy for CLN2 batten disease

A new study shows that delivery of gene therapy to correct the gene mutations that cause CLN2 disease, or Batten disease, directly into the cerebrospinal fluid (CSF) has potential therapeutic effects. The study, conducted ...

Alzheimer's disease & dementia

Panel of 48 CSF proteins complements existing Alzheimer biomarkers

A panel of 48 proteins in the cerebrospinal fluid (CSF 48 panel) complements existing CSF biomarkers for Alzheimer disease (AD), according to a study published in the Sept. 6 issue of Science Translational Medicine.

Genetics

Potential new biomarker for Alzheimer's discovered

Alzheimer's is considered a disease of old age, with most people being diagnosed after 65. But the condition actually begins developing, out of sight, many years before any symptoms emerge. Tiny proteins, known as amyloid-beta ...

page 5 from 36